An entropic safety catch controls Hepatitis C virus entry and antibody resistance

  1. Lenka Stejskal
  2. Mphatso D Kalemera
  3. Charlotte B Lewis
  4. Machaela Palor
  5. Lucas Walker
  6. Tina Daviter
  7. William D Lees
  8. David S Moss
  9. Myrto Kremyda-Vlachou
  10. Zisis Zisis Kozlakidis
  11. Giulia Gallo
  12. Dalan Bailey
  13. William Rosenberg
  14. Christopher JR Illingworth
  15. Adrian J Shepherd
  16. Joe Grove  Is a corresponding author
  1. University College London, United Kingdom
  2. University of Glasgow, United Kingdom
  3. Birkbeck, University of London, United Kingdom
  4. World Health Organization, France
  5. The Pirbright Institute, United Kingdom
  6. University of Cambridge, United Kingdom

Abstract

E1 and E2 (E1E2), the fusion proteins of Hepatitis C Virus (HCV), are unlike that of any other virus yet described, and the detailed molecular mechanisms of HCV entry/fusion remain unknown. Hypervariable region-1 (HVR-1) of E2 is a putative intrinsically disordered protein tail. Here, we demonstrate that HVR-1 has an autoinhibitory function that suppresses the activity of E1E2 on free virions; this is dependent on its conformational entropy. Thus, HVR-1 is akin to a safety catch that prevents premature triggering of E1E2 activity. Crucially, this mechanism is turned off by host receptor interactions at the cell surface to allow entry. Mutations that reduce conformational entropy in HVR-1, or genetic deletion of HVR-1, turn off the safety catch to generate hyper-reactive HCV that exhibits enhanced virus entry but is thermally unstable and acutely sensitive to neutralising antibodies. Therefore, the HVR-1 safety catch controls the efficiency of virus entry and maintains resistance to neutralising antibodies. This discovery provides an explanation for the ability of HCV to persist in the face of continual immune assault and represents a novel regulatory mechanism that is likely to be found in other viral fusion machinery.

Data availability

The underlying data for this manuscript are provided as a Source Data file. Full molecular dynamic simulation trajectories are available here: https://zenodo.org/record/4309544

Article and author information

Author details

  1. Lenka Stejskal

    Institute of Immunity and Transplantation, University College London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  2. Mphatso D Kalemera

    Institute of Immunity and Transplantation, University College London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9461-1117
  3. Charlotte B Lewis

    University of Glasgow, Glasgow, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  4. Machaela Palor

    Institute of Immunity and Transplantation, University College London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  5. Lucas Walker

    Institute of Immunity and Transplantation, University College London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  6. Tina Daviter

    Institute of Structural and Molecular Biology, Birkbeck, University of London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  7. William D Lees

    Institute of Structural and Molecular Biology, Birkbeck, University of London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  8. David S Moss

    Institute of Structural and Molecular Biology, Birkbeck, University of London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  9. Myrto Kremyda-Vlachou

    Division of Infection and Immunity, University College London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  10. Zisis Zisis Kozlakidis

    International Agency for Research on Cancer, World Health Organization, Lyon, France
    Competing interests
    The authors declare that no competing interests exist.
  11. Giulia Gallo

    The Pirbright Institute, Pirbright, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  12. Dalan Bailey

    Virus Programme, The Pirbright Institute, Guildford, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5640-2266
  13. William Rosenberg

    Institute for Liver and Digestive Health, University College London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2732-2304
  14. Christopher JR Illingworth

    Department of Genetics, University of Cambridge, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0030-2784
  15. Adrian J Shepherd

    Biological Sciences, Birkbeck, University of London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0194-8613
  16. Joe Grove

    University of Glasgow, Glasgow, United Kingdom
    For correspondence
    Joe.Grove@glasgow.ac.uk
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5390-7579

Funding

Wellcome Trust (107653/Z/15/Z)

  • Joe Grove

Medical Research Council (MC_UU_12014)

  • Joe Grove

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Glenn Randall

Ethics

Human subjects: Fully consented blood samples (for IgG isolation) were collected from HCV+ patients under ethical approval: "Characterising and modifying immune responses in chronic viral hepatitis"; IRAS Number 43993; REC number 11/LO/0421.

Version history

  1. Preprint posted: November 11, 2020 (view preprint)
  2. Received: July 1, 2021
  3. Accepted: June 28, 2022
  4. Accepted Manuscript published: July 7, 2022 (version 1)
  5. Version of Record published: July 28, 2022 (version 2)

Copyright

© 2022, Stejskal et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,021
    Page views
  • 228
    Downloads
  • 5
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Lenka Stejskal
  2. Mphatso D Kalemera
  3. Charlotte B Lewis
  4. Machaela Palor
  5. Lucas Walker
  6. Tina Daviter
  7. William D Lees
  8. David S Moss
  9. Myrto Kremyda-Vlachou
  10. Zisis Zisis Kozlakidis
  11. Giulia Gallo
  12. Dalan Bailey
  13. William Rosenberg
  14. Christopher JR Illingworth
  15. Adrian J Shepherd
  16. Joe Grove
(2022)
An entropic safety catch controls Hepatitis C virus entry and antibody resistance
eLife 11:e71854.
https://doi.org/10.7554/eLife.71854

Share this article

https://doi.org/10.7554/eLife.71854

Further reading

    1. Microbiology and Infectious Disease
    Chiara Andolina, Wouter Graumans ... Teun Bousema
    Research Article

    It is currently unknown whether all Plasmodium falciparum-infected mosquitoes are equally infectious. We assessed sporogonic development using cultured gametocytes in the Netherlands and naturally circulating strains in Burkina Faso. We quantified the number of sporozoites expelled into artificial skin in relation to intact oocysts, ruptured oocysts, and residual salivary gland sporozoites. In laboratory conditions, higher total sporozoite burden was associated with shorter duration of sporogony (p<0.001). Overall, 53% (116/216) of infected Anopheles stephensi mosquitoes expelled sporozoites into artificial skin with a median of 136 expelled sporozoites (interquartile range [IQR], 34–501). There was a strong positive correlation between ruptured oocyst number and salivary gland sporozoite load (ρ = 0.8; p<0.0001) and a weaker positive correlation between salivary gland sporozoite load and number of sporozoites expelled (ρ = 0.35; p=0.0002). In Burkina Faso, Anopheles coluzzii mosquitoes were infected by natural gametocyte carriers. Among salivary gland sporozoite positive mosquitoes, 89% (33/37) expelled sporozoites with a median of 1035 expelled sporozoites (IQR, 171–2969). Again, we observed a strong correlation between ruptured oocyst number and salivary gland sporozoite load (ρ = 0.9; p<0.0001) and a positive correlation between salivary gland sporozoite load and the number of sporozoites expelled (ρ = 0.7; p<0.0001). Several mosquitoes expelled multiple parasite clones during probing. Whilst sporozoite expelling was regularly observed from mosquitoes with low infection burdens, our findings indicate that mosquito infection burden is positively associated with the number of expelled sporozoites. Future work is required to determine the direct implications of these findings for transmission potential.

    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease
    Veronica Teresa Ober, George Boniface Githure ... Michael Boshart
    Research Article

    Cyclic nucleotide binding domains (CNB) confer allosteric regulation by cAMP or cGMP to many signaling proteins, including PKA and PKG. PKA of phylogenetically distant Trypanosoma is the first exception as it is cyclic nucleotide-independent and responsive to nucleoside analogues (Bachmaier et al., 2019). Here, we show that natural nucleosides inosine, guanosine and adenosine are nanomolar affinity CNB ligands and activators of PKA orthologs of the important tropical pathogens Trypanosoma brucei, Trypanosoma cruzi, and Leishmania. The sequence and structural determinants of binding affinity, -specificity and kinase activation of PKAR were established by structure-activity relationship (SAR) analysis, co-crystal structures and mutagenesis. Substitution of two to three amino acids in the binding sites is sufficient for conversion of CNB domains from nucleoside to cyclic nucleotide specificity. In addition, a trypanosomatid-specific C-terminal helix (αD) is required for high affinity binding to CNB-B. The αD helix functions as a lid of the binding site that shields ligands from solvent. Selectivity of guanosine for CNB-B and of adenosine for CNB-A results in synergistic kinase activation at low nanomolar concentration. PKA pulldown from rapid lysis establishes guanosine as the predominant ligand in vivo in T. brucei bloodstream forms, whereas guanosine and adenosine seem to synergize in the procyclic developmental stage in the insect vector. We discuss the versatile use of CNB domains in evolution and recruitment of PKA for novel nucleoside-mediated signaling.